Considering challenges for the new Alzheimer's drugs: Clinical, population, and health system perspectives.

ABSTRACT: Recent approvals of amyloid immunotherapy drugs for early Alzheimer's disease (AD) have been highly controversial. In this piece, we consider challenges from the clinical, population health, and health systems perspectives to the role that the new AD drugs might be expected to play, now and in the future, in alleviating the morbidity caused by AD in the population. Clinically, short-term effects are small, adverse events are frequent, treatment regimens are burdensome, and, crucially, long-term effects are unknown. At a population level, there is always likely to be a trade-off between breadth of access and magnitude of benefit for any given individual. At a health system level, roll out of treatment even for only narrowly-defined patient groups will involve considerable resources to ident

SUBMITTER: Walsh S 

PROVIDER: S-EPMC11497759 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature